Citadel Advisors’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-654,852
| Closed | -$63.5M | – | 10164 |
|
|
2019
Q3 | $63.5M | Buy |
654,852
+22,676
| +4% | +$2.27M | 0.03% | 616 |
|
|
2019
Q2 | $64.7M | Buy |
632,176
+22,469
| +4% | +$2.42M | 0.03% | 593 |
|
|
2019
Q1 | $69.4M | Buy |
609,707
+566,607
| +1,315% | +$41.6M | 0.03% | 534 |
|
|
2018
Q4 | $1.69M | Sell |
43,100
-30,301
| -41% | -$1.31M | ﹤0.01% | 4419 |
|
|
2018
Q3 | $4M | Sell |
73,401
-30,825
| -30% | -$2.11M | ﹤0.01% | 3287 |
|
|
2018
Q2 | $8.63M | Buy |
104,226
+100,487
| +2,688% | +$7.76M | ﹤0.01% | 2102 |
|
|
2018
Q1 | $249K | Sell |
3,739
-24,445
| -87% | -$1.41M | ﹤0.01% | 7019 |
|
|
2017
Q4 | $1.45M | Buy |
28,184
+14,561
| +107% | +$1.05M | ﹤0.01% | 4082 |
|
|
2017
Q3 | $1.22M | Sell |
13,623
-867,281
| -98% | -$65.9M | ﹤0.01% | 4041 |
|
|
2017
Q2 | $52.6M | Buy |
880,904
+787,334
| +841% | +$44M | 0.04% | 475 |
|
|
2017
Q1 | $4.99M | Sell |
93,570
-313,342
| -77% | -$18.6M | ﹤0.01% | 2049 |
|
|
2016
Q4 | $20.3M | Buy |
+406,912
| New | +$21.8M | 0.02% | 864 |
|
|
2016
Q3 | – | Sell |
-12,728
| Closed | -$734K | – | 8040 |
|
|
2016
Q2 | $651K | Buy |
+12,728
| New | +$544K | ﹤0.01% | 4136 |
|
|
2016
Q1 | – | Sell |
-3,896
| Closed | -$123K | – | 8552 |
|
|
2015
Q4 | $177K | Sell |
3,896
-16,344
| -81% | -$857K | ﹤0.01% | 5960 |
|
|
2015
Q3 | $845K | Buy |
20,240
+15,987
| +376% | +$834K | ﹤0.01% | 4040 |
|
|
2015
Q2 | $256K | Buy |
4,253
+1,885
| +80% | +$125K | ﹤0.01% | 5983 |
|
|
2015
Q1 | $184K | Buy |
+2,368
| New | +$136K | ﹤0.01% | 6278 |
|
Citadel Advisors's ONCE Position: Q4 2019 in Review
Citadel Advisors sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 654,852 shares — an estimated $63.5M sold.
Citadel Advisors first reported a position in ONCE in Q1 2015 and held it in 17 quarters. The position peaked at $69.4M in Q1 2019. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.
- Citadel Advisors reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
- Citadel Advisors sold 654,852 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $63.5M.
- Citadel Advisors first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 17 quarters.
- Citadel Advisors's Spark Therapeutics, Inc. Common Stock position peaked at $69.4M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.
Based on Citadel Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.